IBB holdings
iShares Biotechnology ETF
Positions
252 stored of 252 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds III BlackRock Cash Funds: Institutional, SL Agency Shares | US0669225197 | 066922519 | 11.661% | $1.1B | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 2 | Vertex Pharmaceuticals, Inc. | US92532F1003 | 92532F100 | 8.080% | $734.3M | Equity (common) | Corporate | United States | USD |
| 3 | Amgen, Inc. | US0311621009 | 031162100 | 7.828% | $711.4M | Equity (common) | Corporate | United States | USD |
| 4 | Gilead Sciences, Inc. | US3755581036 | 375558103 | 6.842% | $621.8M | Equity (common) | Corporate | United States | USD |
| 5 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 75886F107 | 4.906% | $445.9M | Equity (common) | Corporate | United States | USD |
| 6 | Argenx SE | US04016X1019 | 04016X101 | 3.759% | $341.6M | Equity (common) | Corporate | Netherlands | USD |
| 7 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 02043Q107 | 3.121% | $283.6M | Equity (common) | Corporate | United States | USD |
| 8 | Natera, Inc. | US6323071042 | 632307104 | 2.891% | $262.7M | Equity (common) | Corporate | United States | USD |
| 9 | Revolution Medicines, Inc. | US76155X1000 | 76155X100 | 2.780% | $252.7M | Equity (common) | Corporate | United States | USD |
| 10 | Biogen, Inc. | US09062X1037 | 09062X103 | 2.466% | $224.1M | Equity (common) | Corporate | United States | USD |
| 11 | Illumina, Inc. | US4523271090 | 452327109 | 2.069% | $188.0M | Equity (common) | Corporate | United States | USD |
| 12 | Moderna, Inc. | US60770K1079 | 60770K107 | 1.984% | $180.3M | Equity (common) | Corporate | United States | USD |
| 13 | Insmed, Inc. | US4576693075 | 457669307 | 1.785% | $162.2M | Equity (common) | Corporate | United States | USD |
| 14 | BeOne Medicines Ltd. | US07725L1026 | 07725L102 | 1.769% | $160.8M | Equity (common) | Corporate | Switzerland | USD |
| 15 | Incyte Corp. | US45337C1027 | 45337C102 | 1.750% | $159.0M | Equity (common) | Corporate | United States | USD |
| 16 | United Therapeutics Corp. | US91307C1027 | 91307C102 | 1.734% | $157.6M | Equity (common) | Corporate | United States | USD |
| 17 | Roivant Sciences Ltd. | BMG762791017 | Not reported | 1.426% | $129.6M | Equity (common) | Corporate | Bermuda | USD |
| 18 | Neurocrine Biosciences, Inc. | US64125C1099 | 64125C109 | 1.298% | $118.0M | Equity (common) | Corporate | United States | USD |
| 19 | Ascendis Pharma A/S | DK0060615755 | Not reported | 1.286% | $116.9M | Equity (common) | Corporate | Denmark | USD |
| 20 | Genmab A/S | US3723032062 | 372303206 | 1.119% | $101.7M | Equity (common) | Corporate | Denmark | USD |
| 21 | Exelixis, Inc. | US30161Q1040 | 30161Q104 | 1.033% | $93.9M | Equity (common) | Corporate | United States | USD |
| 22 | Ionis Pharmaceuticals, Inc. | US4622221004 | 462222100 | 1.002% | $91.1M | Equity (common) | Corporate | United States | USD |
| 23 | Bridgebio Pharma, Inc. | US10806X1028 | 10806X102 | 0.982% | $89.2M | Equity (common) | Corporate | United States | USD |
| 24 | Medpace Holdings, Inc. | US58506Q1094 | 58506Q109 | 0.950% | $86.3M | Equity (common) | Corporate | United States | USD |
| 25 | Madrigal Pharmaceuticals, Inc. | US5588681057 | 558868105 | 0.908% | $82.5M | Equity (common) | Corporate | United States | USD |
| 26 | Bio-Techne Corp. | US09073M1045 | 09073M104 | 0.859% | $78.1M | Equity (common) | Corporate | United States | USD |
| 27 | BioMarin Pharmaceutical, Inc. | US09061G1013 | 09061G101 | 0.849% | $77.2M | Equity (common) | Corporate | United States | USD |
| 28 | Charles River Laboratories International, Inc. | US1598641074 | 159864107 | 0.842% | $76.5M | Equity (common) | Corporate | United States | USD |
| 29 | Arrowhead Pharmaceuticals, Inc. | US04280A1007 | 04280A100 | 0.841% | $76.4M | Equity (common) | Corporate | United States | USD |
| 30 | Axsome Therapeutics, Inc. | US05464T1043 | 05464T104 | 0.822% | $74.7M | Equity (common) | Corporate | United States | USD |
| 31 | Cytokinetics, Inc. | US23282W6057 | 23282W605 | 0.792% | $71.9M | Equity (common) | Corporate | United States | USD |
| 32 | Krystal Biotech, Inc. | US5011471027 | 501147102 | 0.746% | $67.8M | Equity (common) | Corporate | United States | USD |
| 33 | Halozyme Therapeutics, Inc. | US40637H1095 | 40637H109 | 0.716% | $65.1M | Equity (common) | Corporate | United States | USD |
| 34 | Praxis Precision Medicines, Inc. | US74006W2070 | 74006W207 | 0.682% | $61.9M | Equity (common) | Corporate | United States | USD |
| 35 | Abivax SA | US00370M1036 | 00370M103 | 0.673% | $61.1M | Equity (common) | Corporate | France | USD |
| 36 | Alkermes plc | IE00B56GVS15 | Not reported | 0.666% | $60.5M | Equity (common) | Corporate | Ireland | USD |
| 37 | BioNTech SE | US09075V1026 | 09075V102 | 0.663% | $60.2M | Equity (common) | Corporate | Germany | USD |
| 38 | Vaxcyte, Inc. | US92243G1085 | 92243G108 | 0.640% | $58.2M | Equity (common) | Corporate | United States | USD |
| 39 | Kymera Therapeutics, Inc. | US5015751044 | 501575104 | 0.636% | $57.8M | Equity (common) | Corporate | United States | USD |
| 40 | Apogee Therapeutics, Inc. | US03770N1019 | 03770N101 | 0.590% | $53.6M | Equity (common) | Corporate | United States | USD |
| 41 | Protagonist Therapeutics, Inc. | US74366E1029 | 74366E102 | 0.583% | $53.0M | Equity (common) | Corporate | United States | USD |
| 42 | Rhythm Pharmaceuticals, Inc. | US76243J1051 | 76243J105 | 0.575% | $52.2M | Equity (common) | Corporate | United States | USD |
| 43 | Repligen Corp. | US7599161095 | 759916109 | 0.568% | $51.6M | Equity (common) | Corporate | United States | USD |
| 44 | Spyre Therapeutics, Inc. | US00773J2024 | 00773J202 | 0.535% | $48.6M | Equity (common) | Corporate | United States | USD |
| 45 | Bruker Corp. | US1167941087 | 116794108 | 0.522% | $47.4M | Equity (common) | Corporate | United States | USD |
| 46 | PTC Therapeutics, Inc. | US69366J2006 | 69366J200 | 0.510% | $46.3M | Equity (common) | Corporate | United States | USD |
| 47 | Nuvalent, Inc. Nuvalent, Inc., Class A | US6707031075 | 670703107 | 0.503% | $45.7M | Equity (common) | Corporate | United States | USD |
| 48 | Twist Bioscience Corp. | US90184D1000 | 90184D100 | 0.478% | $43.4M | Equity (common) | Corporate | United States | USD |
| 49 | Tempus AI, Inc. Tempus AI, Inc., Class A | US88023B1035 | 88023B103 | 0.477% | $43.4M | Equity (common) | Corporate | United States | USD |
| 50 | Mirum Pharmaceuticals, Inc. | US6047491013 | 604749101 | 0.453% | $41.1M | Equity (common) | Corporate | United States | USD |
| 51 | Cogent Biosciences, Inc. | US19240Q2012 | 19240Q201 | 0.444% | $40.3M | Equity (common) | Corporate | United States | USD |
| 52 | Xenon Pharmaceuticals, Inc. | CA98420N1050 | 98420N105 | 0.427% | $38.8M | Equity (common) | Corporate | Canada | USD |
| 53 | Scholar Rock Holding Corp. | US80706P1030 | 80706P103 | 0.414% | $37.6M | Equity (common) | Corporate | United States | USD |
| 54 | Travere Therapeutics, Inc. | US89422G1076 | 89422G107 | 0.400% | $36.4M | Equity (common) | Corporate | United States | USD |
| 55 | Definium Therapeutics, Inc. | CA24477V1058 | 24477V105 | 0.385% | $35.0M | Equity (common) | Corporate | Canada | USD |
| 56 | CRISPR Therapeutics AG | CH0334081137 | Not reported | 0.381% | $34.6M | Equity (common) | Corporate | Switzerland | USD |
| 57 | BlackRock Funds III BlackRock Cash Funds: Treasury, SL Agency Shares | US0669224778 | 066922477 | 0.377% | $34.3M | Short-term investment vehicles (cash funds) | Registered fund | United States | USD |
| 58 | Oruka Therapeutics, Inc. | US6876041087 | 687604108 | 0.376% | $34.2M | Equity (common) | Corporate | United States | USD |
| 59 | Veracyte, Inc. | US92337F1075 | 92337F107 | 0.356% | $32.4M | Equity (common) | Corporate | United States | USD |
| 60 | 10X Genomics, Inc. 10X Genomics, Inc., Class A | US88025U1097 | 88025U109 | 0.337% | $30.6M | Equity (common) | Corporate | United States | USD |
| 61 | Legend Biotech Corp. | US52490G1022 | 52490G102 | 0.335% | $30.4M | Equity (common) | Corporate | Cayman Islands | USD |
| 62 | ACADIA Pharmaceuticals, Inc. | US0042251084 | 004225108 | 0.333% | $30.3M | Equity (common) | Corporate | United States | USD |
| 63 | CG oncology, Inc. | US1569441009 | 156944100 | 0.318% | $28.9M | Equity (common) | Corporate | United States | USD |
| 64 | Denali Therapeutics, Inc. | US24823R1059 | 24823R105 | 0.298% | $27.1M | Equity (common) | Corporate | United States | USD |
| 65 | Crinetics Pharmaceuticals, Inc. | US22663K1079 | 22663K107 | 0.285% | $25.9M | Equity (common) | Corporate | United States | USD |
| 66 | Erasca, Inc. | US29479A1088 | 29479A108 | 0.267% | $24.3M | Equity (common) | Corporate | United States | USD |
| 67 | Tango Therapeutics, Inc. | US87583X1090 | 87583X109 | 0.258% | $23.5M | Equity (common) | Corporate | United States | USD |
| 68 | Adaptive Biotechnologies Corp. | US00650F1093 | 00650F109 | 0.258% | $23.5M | Equity (common) | Corporate | United States | USD |
| 69 | ImmunityBio, Inc. | US45256X1037 | 45256X103 | 0.257% | $23.3M | Equity (common) | Corporate | United States | USD |
| 70 | Beam Therapeutics, Inc. | US07373V1052 | 07373V105 | 0.251% | $22.8M | Equity (common) | Corporate | United States | USD |
| 71 | Edgewise Therapeutics, Inc. | US28036F1057 | 28036F105 | 0.249% | $22.6M | Equity (common) | Corporate | United States | USD |
| 72 | Structure Therapeutics, Inc. | US86366E1064 | 86366E106 | 0.245% | $22.2M | Equity (common) | Corporate | Cayman Islands | USD |
| 73 | Immunovant, Inc. | US45258J1025 | 45258J102 | 0.243% | $22.1M | Equity (common) | Corporate | United States | USD |
| 74 | Ideaya Biosciences, Inc. | US45166A1025 | 45166A102 | 0.241% | $21.9M | Equity (common) | Corporate | United States | USD |
| 75 | Ultragenyx Pharmaceutical, Inc. | US90400D1081 | 90400D108 | 0.233% | $21.2M | Equity (common) | Corporate | United States | USD |
| 76 | Dyne Therapeutics, Inc. | US26818M1080 | 26818M108 | 0.229% | $20.8M | Equity (common) | Corporate | United States | USD |
| 77 | Arcutis Biotherapeutics, Inc. | US03969K1088 | 03969K108 | 0.226% | $20.5M | Equity (common) | Corporate | United States | USD |
| 78 | Newamsterdam Pharma Co. NV | NL00150012L7 | Not reported | 0.211% | $19.2M | Equity (common) | Corporate | Netherlands | USD |
| 79 | GRAIL, Inc. | US3847471014 | 384747101 | 0.211% | $19.2M | Equity (common) | Corporate | United States | USD |
| 80 | Relay Therapeutics, Inc. | US75943R1023 | 75943R102 | 0.209% | $19.0M | Equity (common) | Corporate | United States | USD |
| 81 | uniQure NV | NL0010696654 | Not reported | 0.202% | $18.4M | Equity (common) | Corporate | Netherlands | USD |
| 82 | Arcus Biosciences, Inc. | US03969F1093 | 03969F109 | 0.201% | $18.3M | Equity (common) | Corporate | United States | USD |
| 83 | Tarsus Pharmaceuticals, Inc. | US87650L1035 | 87650L103 | 0.198% | $18.0M | Equity (common) | Corporate | United States | USD |
| 84 | Vera Therapeutics, Inc. Vera Therapeutics, Inc., Class A | US92337R1014 | 92337R101 | 0.196% | $17.8M | Equity (common) | Corporate | United States | USD |
| 85 | Enliven Therapeutics, Inc. | US29337E1029 | 29337E102 | 0.186% | $16.9M | Equity (common) | Corporate | United States | USD |
| 86 | Nurix Therapeutics, Inc. | US67080M1036 | 67080M103 | 0.186% | $16.9M | Equity (common) | Corporate | United States | USD |
| 87 | Alumis, Inc. | US0223071020 | 022307102 | 0.184% | $16.7M | Equity (common) | Corporate | United States | USD |
| 88 | Kodiak Sciences, Inc. | US50015M1099 | 50015M109 | 0.176% | $16.0M | Equity (common) | Corporate | United States | USD |
| 89 | Vericel Corp. | US92346J1088 | 92346J108 | 0.175% | $15.9M | Equity (common) | Corporate | United States | USD |
| 90 | Intellia Therapeutics, Inc. | US45826J1051 | 45826J105 | 0.175% | $15.9M | Equity (common) | Corporate | United States | USD |
| 91 | Caris Life Sciences, Inc. | US1421521071 | 142152107 | 0.170% | $15.5M | Equity (common) | Corporate | United States | USD |
| 92 | BioCryst Pharmaceuticals, Inc. | US09058V1035 | 09058V103 | 0.168% | $15.3M | Equity (common) | Corporate | United States | USD |
| 93 | Agios Pharmaceuticals, Inc. | US00847X1046 | 00847X104 | 0.161% | $14.7M | Equity (common) | Corporate | United States | USD |
| 94 | Disc Medicine, Inc. | US2546041011 | 254604101 | 0.158% | $14.4M | Equity (common) | Corporate | United States | USD |
| 95 | Summit Therapeutics, Inc. | US86627T1088 | 86627T108 | 0.153% | $13.9M | Equity (common) | Corporate | United States | USD |
| 96 | Aurinia Pharmaceuticals, Inc. | CA05156V1022 | 05156V102 | 0.150% | $13.6M | Equity (common) | Corporate | Canada | USD |
| 97 | ADMA Biologics, Inc. | US0008991046 | 000899104 | 0.147% | $13.4M | Equity (common) | Corporate | United States | USD |
| 98 | Biohaven Ltd. | VGG1110E1079 | Not reported | 0.146% | $13.2M | Equity (common) | Corporate | British Virgin Islands | USD |
| 99 | Zymeworks, Inc. | US98985Y1082 | 98985Y108 | 0.144% | $13.1M | Equity (common) | Corporate | United States | USD |
| 100 | AnaptysBio, Inc. | US0327241065 | 032724106 | 0.144% | $13.1M | Equity (common) | Corporate | United States | USD |